Skip to main content
Journal cover image

Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.

Publication ,  Journal Article
Mayo-Wilson, E; Fusco, N; Li, T; Hong, H; Canner, JK; Dickersin, K; MUDS investigators,
Published in: J Clin Epidemiol
September 2019

OBJECTIVE: We examined nonsystematic adverse events (AEs) in Part 2 (of 2) of a study describing the assessment and reporting AEs in clinical trials. STUDY DESIGN AND SETTING: We examined 21 trials of gabapentin for neuropathic pain (52 sources) and seven trials of quetiapine for bipolar depression (80 sources) using data from the Multiple Data Sources study. We extracted and compared information about nonsystematic AEs (i.e., AEs that were not assessed for every participant), including AEs categorized as "serious." We recorded whether AEs were grouped by anatomic or physiological system. RESULTS: Trials of the same drug reported information about different AEs. Information in public sources was inadequate for decision-making. No public source reported all AEs, or all serious AEs, identified in nonpublic sources about the same trial. Of trials with only public sources, 2/15 (13%) gabapentin and 0/3 (0%) quetiapine trials grouped AEs by anatomic or physiological system. CONCLUSION: Public sources contained little information about nonsystematic AEs, including serious AEs. Grouping might make nonsystematic AEs easier to detect; however, most public sources did not report grouped AEs. Standards are needed to improve the collection and reporting of nonsystematic AEs so that stakeholders can use trials to assess the balance of potential benefits and harms.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Epidemiol

DOI

EISSN

1878-5921

Publication Date

September 2019

Volume

113

Start / End Page

11 / 19

Location

United States

Related Subject Headings

  • Research Report
  • Randomized Controlled Trials as Topic
  • Quetiapine Fumarate
  • Neuralgia
  • Humans
  • Gabapentin
  • Epidemiology
  • Drug-Related Side Effects and Adverse Reactions
  • Data Accuracy
  • Bipolar Disorder
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J. K., Dickersin, K., & MUDS investigators, . (2019). Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. J Clin Epidemiol, 113, 11–19. https://doi.org/10.1016/j.jclinepi.2019.04.020
Mayo-Wilson, Evan, Nicole Fusco, Tianjing Li, Hwanhee Hong, Joseph K. Canner, Kay Dickersin, and Kay MUDS investigators. “Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.J Clin Epidemiol 113 (September 2019): 11–19. https://doi.org/10.1016/j.jclinepi.2019.04.020.
Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K, et al. Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. J Clin Epidemiol. 2019 Sep;113:11–9.
Mayo-Wilson, Evan, et al. “Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.J Clin Epidemiol, vol. 113, Sept. 2019, pp. 11–19. Pubmed, doi:10.1016/j.jclinepi.2019.04.020.
Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K, MUDS investigators. Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. J Clin Epidemiol. 2019 Sep;113:11–19.
Journal cover image

Published In

J Clin Epidemiol

DOI

EISSN

1878-5921

Publication Date

September 2019

Volume

113

Start / End Page

11 / 19

Location

United States

Related Subject Headings

  • Research Report
  • Randomized Controlled Trials as Topic
  • Quetiapine Fumarate
  • Neuralgia
  • Humans
  • Gabapentin
  • Epidemiology
  • Drug-Related Side Effects and Adverse Reactions
  • Data Accuracy
  • Bipolar Disorder